Shelley Idziaszczyk

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Tim Maughan, Richard Adams, Christopher G. Smith et al. · The Lancet · 2011 · 967 citations

Medicine, Oncology, Pharmacology +12

Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33

Richard S. Houlston, Jeremy P. Cheadle, Sara E. Dobbins et al. · Nature Genetics · 2010 · 374 citations · Full text

Life Sciences, Genetics, Oncology +14

Molecular Genetic and Phenotypic Analysis Reveals Differences between TSC1 and TSC2 Associated Familial and Sporadic Tuberous Sclerosis

Adriane C. Jones, C. Daniells, Russell G. Snell et al. · Human Molecular Genetics · 1997 · 257 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer

Henry Rodriguez‐Broadbent, Philip Law, Amit Sud et al. · International Journal of Cancer · 2017 · 109 citations · Full text

Life Sciences, Genetics, Oncology +16

Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

Christopher G. Smith, David J. Fisher, Bart Claes et al. · Clinical Cancer Research · 2013 · 108 citations · Full text

Medicine, Oncology, Pharmacology +17